Portal:AOP/FeaturedPathways
From WikiPathways
(Difference between revisions)
| Line 43: | Line 43: | ||
* [[Pathway:WP3181]] | * [[Pathway:WP3181]] | ||
* [[Pathway:WP4891]] | * [[Pathway:WP4891]] | ||
| + | * [[Pathway:WP4914]] | ||
| + | * [[Pathway:WP4944]] | ||
| + | * [[Pathway:WP4945]] | ||
Revision as of 10:21, 7 August 2020
|
Image does not exist COVID-19 AOP (Homo sapiens) |
Image does not exist Mitochondrial Complex I inhibition leading to parkinsonian motor deficits (Homo sapiens) |
Image does not exist Mitochondrial Complex I inhibition leading to chemical induced fanconi syndrome (Homo sapiens) |
Image does not exist Adverse Outcome Pathway (AOP) for Mitochondrial Complex 1 (C1) inhibition (Homo sapiens) |
|
Image does not exist Protein alkylation leading to liver fibrosis (Homo sapiens) |
Image does not exist Lung fibrosis (Homo sapiens) |
Image does not exist Lung fibrosis (Mus musculus) |
Image does not exist Epilepsy Adverse Outcome Pathway (Homo sapiens) |
|
Image does not exist Liver steatosis AOP (Homo sapiens) |
Image does not exist Steatosis AOP (Homo sapiens) |
Image does not exist Selective serotonin reuptake inhibitors lead to several adverse outcomes (Homo sapiens) |
Image does not exist Gastric ulcer formation (Homo sapiens) |
|
Image does not exist Nanoparticle-mediated activation of receptor signaling (Homo sapiens) |
Image does not exist Nanomaterial induced apoptosis (Homo sapiens) |
Image does not exist Nanoparticle triggered regulated necrosis (Homo sapiens) |
Image does not exist Nanoparticle triggered autophagic cell death (Homo sapiens) |
|
Image does not exist Overview of nanoparticle effects (Homo sapiens) |
Image does not exist Nanomaterial induced inflammasome activation (Homo sapiens) |
Image does not exist Nanoparticle-mediated activation of receptor signaling (Bos taurus) |
List of featured pathways:
